% | $
Quotes you view appear here for quick access.

Altria Group Inc. Message Board

  • rodentologist Jan 18, 2013 1:05 PM Flag

    Oh rodentess....

    Rodentess, you still haven't explained how you "know" Hansen is Jewish?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The Diabetes-Mental Illness Link:
      Clinical Applications
      Beyond Atypical Antipsychotics
      By Caroline Helwick

      Amsterdam, the Netherlands—The relationship between diabetes mellitus and mental illness is an
      established reality, even though the pathophysiology of this association has not been well defined and its clinical implications not fully realized. At the European Association for the Study of Diabetes, this topic was explored by a number of experts. For reasons still not fully understood, the prevalence of diabetes among patients with severe mental illness
      is 2 to 3 times higher than in the general population. Although this disproportionate risk has largely been attributed to treatment with some of the second-generation (atypical) antipsychotic medications, Stephen Gough, MD, professor of medicine at the University of Birmingham, England, said, "I think the link goes well beyond this."

      A recent study that involved 200 Dutch patients (Diabetes Care. 2006; 29:786-791) showed that the
      prevalence of diabetes was 14.5% among those with severe mental illness compared with 1.5% in the general population. Based on other published studies, Dr Gough maintained that the association is multifactorial, involving not only antipsychotic agents but also unhealthy lifestyle and biologic factors.

      A family history of type 2 diabetes has been found in up to 30% of patients with schizophrenia. There are overlaps in gene regions encoding for diabetes and schizophrenia and overlaps in the regulatory enzymes for glycolysis and schizophrenia. An association has also been shown between psychosis, beta-cell function, and insulin resistance. As psychosis improves, so do beta-cell function and insulin resistance, Dr Gough said, citing a 2003 study (Diabetes Care. 2003;26:1462-1467). Jogin H. Thakore, PhD, of St. Vincent's Hospital, Dublin, Ireland, further noted that persons with newly diagnosed schizophrenia have 3 times as much intraabdominal fat as matched controls. Impaired glucose tolerance is found in 15% of these individuals and in 18% of their first-degree relatives. Patients with schizophrenia also have increased expression of a surface-bound platelet glycoprotein that is critical to
      platelet aggregation. "This may partly explain the increased predisposition of the severely mentally ill to cardiac events," Dr Thakore said.

      Screen Mentally Ill Patients for Glucose Tolerance
      Coronary artery disease is the leading cause of death among the severely mentally ill.
      This population has triple the mortality rate of the general population, with patients
      dying 10 to 20 years earlier than the general population—possibly because of the
      prevalence of diabetes and the metabolic syndrome, according to Richard Holt, PhD,
      MRCP, of the University of Southampton, United Kingdom.
      The Clinical Antipsychotic Trials of Intervention Effectiveness study (Schizophr Res.
      2005;80:19-32) demonstrated that more than 85% of patients with schizophrenia
      had at least 1 feature of the metabolic syndrome.

      "The management of metabolic predictors in patients with severe mental illness is a neglected area," Dr Holt said. He recommended screening for glucose tolerance before starting antipsychotic therapy. Treatment can be challenging, he acknowledged. There may be less awareness of symptoms related to d iabetes confo nding medical conditions and an inabilit to manage antidiabetic medications "B t j st
      Normal Version
      Richard Holt,
      PhD, MRCP
      reliably measuring cardiovascular risk factors and treating these patients as you would treat the general
      public would be a great leap forward," he said.
      Atypical Antipsychotics and New-Onset Diabetes
      The role of the second-generation antipsychotics in the development of new-onset type 2 diabetes in
      patients with schizophrenia has been recently actively explored. A new study quantified the potential risk of
      treatment-emergent diabetes in 15 pharmacoepidemiologic studies (Ann Pharmacother. 2007;41:1593-
      1603). Lead author Leslie Citrome, MD, MPH, of the New York University School of Medicine, presented the
      results at the meeting.
      Attributable risk was determined by calculating the number needed to treat to produce 1 case of diabetes.
      Altogether, the second-generation antipsychotics were associated with a range of from 53 more cases to 46
      fewer cases of diabetes per 1000 patients compared with the first-generation antipsychotics; however, few
      studies controlled for confounding factors, such as body weight, family history, and physical activity, Dr
      Citrome pointed out.
      In spite of the propensity for some agents to cause weight gain and dyslipidemia, the study showed little
      difference between individual second-generation antipsychotics and first-generation antipsychotics.
      "Although prolonged exposure to an individual agent can cause problems, the attributable risk remains
      unknown. The choice of antipsychotic cannot predict who will develop type 2 diabetes," Dr Citrome said,
      adding that side effects must be balanced against the need for efficacious psychiatric treatment.
      Depression Treatment Improves Diabetes Outcomes
      Other forms of mental illness are also intertwined with diabetes. Major depressive
      disorder occurs in 10%, and subclinical depression in 10% to 40%, of persons with
      diabetes. On the flip side, depressed persons have a greatly increased risk of
      developing type 2 diabetes compared with nondepressed persons, and when the 2
      conditions coexist, diabetic outcomes worsen, said Patrick J. Lustman, MD, of
      Washington University, St. Louis.
      For example, a study stratifying patients with diabetes by depression scores (Am J
      Epidemiol. 2005;161:652-660) showed a 54% increase in mortality among the most
      severely depressed, but even subclinical depression was associated with some risk.
      Other studies have also found mortality risk to be greatly increased for patients with
      both diabetes and depression (Diabetes Care. 2005;28:1339-1345). "Depression
      somehow causes a susceptibility to dying," Dr Lustman concluded.
      Among patients with diabetes, those who are depressed have poorer glycemic control compared with those
      who are not depressed, a higher risk of comorbidities and mortality, increased functional impairment, and
      poorer adherence to diet, exercise, and self-management strategies, said Norbert Hermanns, PhD, of the
      Research Institute of the Diabetes Academy Mergentheim, Bad Mergentheim, Germany.
      Depression also appears to increase the risk of developing diabetes. In the prospective Stockholm Diabetes
      Prevention Program of 5500 patients, men (but not women) with the highest level of depressive symptoms
      had a nearly 4-fold greater risk for type 2 diabetes, and a nearly 2-fold greater risk for a prediabetic state,
      compared with the least depressed, reported Claes-Göran Östenson, MD, of the Karolinska Institute,
      Stockholm, Sweden.
      Based on such emerging data, Dr Hermanns emphasized, "Depression in diabetes has to be taken
      seriously." The recent World Health Survey (Lancet. 2007;370:851-858) showed that the combination of
      diabetes and depression has the most negative impact on health among a dozen or so serious medical
      Despite its seriousness, depression remains undetected and untreated in 50% to 75% of patients with
      diabetes Sc eening can help b t it has a "disappointing" effect on the ltimate management of dep ession

    • maybe he is circumcised.

63.32+0.29(+0.46%)Sep 27 4:01 PMEDT